Severe Label Expansion for EVO Products Trial

Launched by PROSOMNUS SLEEP TECHNOLOGIES · Jul 24, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how safe and effective the EVO Sleep and Snore Device is for treating people with severe obstructive sleep apnea (OSA), a condition where breathing repeatedly stops or becomes very shallow during sleep. The EVO device is a small mouthpiece that helps keep the airway open by gently moving the lower jaw forward. While it’s already approved for mild to moderate OSA, this study aims to see if it also works well for those with more severe cases.

Adults aged 18 to 80 with severe OSA who don’t have other serious health problems or breathing issues may be eligible to join. To participate, you’ll need to agree to follow the study’s procedures and attend all appointments over about six months. During the study, participants will use the EVO device and have their sleep monitored at the start and after six months to check how much their breathing improves. The study will also carefully track any side effects or problems related to using the device. This trial will take place at a few locations and plans to enroll up to 49 people. If you have severe sleep apnea and are interested in alternatives to other treatments like CPAP, this study might be an option to consider.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Provision of signed and dated informed consent form
• • 2. Stated willingness to comply with all study procedures and availability for the duration of the study
• • 3. Male or female, aged 18-80 years (inclusive)
• 4. Diagnosed with uncomplicated severe OSA (AHI \> 30 h-1); where uncomplicated is defined by the absence of:
• • 1. Conditions that place the patient at increased risk of non-obstructive sleep-disordered breathing (e.g., central sleep apnea, hypoventilation, and sleep-related hypoxemia \[e.g., resulting from severe chronic obstructive, interstitial lung disease, or pulmonary hypertension\]). Examples of such conditions include significant cardiopulmonary disease (congestive heart failure, recurrent atrial fibrillation, coronary artery disease, resistant hypertension), potential respiratory muscle weakness due to neuromuscular conditions, history of stroke, and chronic opiate medication use.
• • 2. Concern for significant non-respiratory sleep disorder(s) that require evaluation (e.g., disorders of central hypersomnolence, parasomnias, sleep-related movement disorders) or interfere with accuracy of HSAT (e.g., severe insomnia).
• • 3. Environmental or personal factors that preclude the adequate acquisition and interpretation of data from HSAT.
• • 5. Body mass index (BMI) \< 35 kg/m2
• • 6. Absence of severe oxyhemoglobin desaturation during sleep, indicated by mean nocturnal SpO2 \> 87%
• • 7. Adequate mandibular range of motion
• • 8. Adequate dentition
• Exclusion Criteria:
• An individual who meets any of the following criteria will be excluded from participation in this study:
• • 1. Inability to breathe through the nose comfortably
• • 2. Presence of \> 25% CSA
• • 3. Presence of positional OSA per Amsterdam Positional OSA Classification I definition
• • 4. History of surgery intended to alter anatomy for the correction of OSA
• • 1. E.g., uvulopalatopharyngoplasty (UPPP), maxillomandibular advancement (MMA), tongue/hyoid suspension, slow maxillary expansion
• • 2. History of surgery intended to restore normal anatomy, such as tonsillectomy, adenoidectomy, septoplasty, or polypectomy, is permitted.
• • 5. Presence of hypoglossal nerve stimulation device (active or inactive)
• • 6. Use of CPAP or OAT within the two weeks prior to the baseline sleep study
• • 7. History of OAT that has been confirmed to provide effective therapy within the two years prior to the baseline sleep study
• • 8. Anticipated change in medical therapy during the study protocol that could alter OSA severity (e.g., weight loss surgery, weight loss drug, UPPP, MMA, tongue/hyoid suspension, etc.)
• • 9. Loose teeth or advanced periodontal disease
• • 10. History of temporomandibular joint disorder
• • 11. Resistant hypertension, defined as inadequately controlled blood pressure despite therapy with
• • ≥ 3 oral hypertensive agents
• • 12. Use of pacemaker or other life-supporting device
• • 13. Participation in other studies that could interfere with the study protocol
• • 14. Pregnancy or lactation
• • 15. In the opinion of the investigator, unsuitable for inclusion in the study